Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus rhamnosus-derived extracellular vesicles
- Development stage
- Preclinical
- Lead developer
- Ocean University of China
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Rectal, Intravenous
01
Overview
Lactobacillus rhamnosus-derived extracellular vesicles (LGG-EVs) are nanoparticles released by the probiotic bacterium *Lactobacillus rhamnosus* GG. They are being investigated for their therapeutic potential in inflammatory conditions, particularly inflammatory bowel disease (IBD) such as ulcerative colitis. [1, 9] Preclinical studies in mice with DSS-induced colitis have shown that LGG-EVs can reduce intestinal inflammation and tissue damage. [1, 4] The proposed mechanism of action involves the inhibition of the TLR4-NF-κB-NLRP3 signaling pathway, which leads to a decrease in pro-inflammatory cytokines like TNF-α, IL-1β, and IL-6. [1, 2, 3] Additionally, LGG-EVs have been observed to modulate the gut microbiota, restoring a healthier composition in diseased models. [1, 3]
- Brand names
- LGG-EVs
- Other names
- Lactobacillus rhamnosus GG derived extracellular vesiclesL. rhamnosus GG-EVs
02
Targets
NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on lactobacillus rhamnosus-derived extracellular vesicles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus rhamnosus-derived extracellular vesicles.